<SEC-DOCUMENT>0001171843-23-005961.txt : 20231002
<SEC-HEADER>0001171843-23-005961.hdr.sgml : 20231002
<ACCEPTANCE-DATETIME>20231002060505
ACCESSION NUMBER:		0001171843-23-005961
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20231002
FILED AS OF DATE:		20231002
DATE AS OF CHANGE:		20231002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		231297598

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_100223.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&#160;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>FORM 6-K</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0">&#160;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PURSUANT TO RULE 13a-16 or 15d-16 OF</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&#160;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Report on Form 6-K dated October 2, 2023</b></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Commission File No. 1-15024)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&#160;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&#160;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>Novartis AG</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Name of Registrant)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&#160;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Lichtstrasse 35</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>4056 Basel</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Switzerland</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Address of Principal Executive Offices)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&#160;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&#160;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Form 20-F:&#160;&#9746;</B></FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt">&#160;</TD>
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Form 40-F:&#160;&#9744;</FONT></TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&#160;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark whether the registrant by furnishing the information contained in
this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&#160;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&#160;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&#160;<B>&#9746;</B></FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&#160;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&#160;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%"><IMG SRC="logo.jpg" ALT=""><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="width: 33%">
        <p style="color: rgb(4,96,169); font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>Novartis&#160;International&#160;AG<BR> Novartis&#160;Global
        Communications</b><BR> <font style="color: windowtext">CH-4002 Basel</font><BR> <font style="color: windowtext">Switzerland</font></P>
        <p style="color: #0460A9; font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&#160;</P>
        <p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">https://www.novartis.com</P>
        <P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">https://twitter.com/novartisnews</P> </TD></TR>
  </TABLE>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&#160;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&#160;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></font></p>

<p style="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(141,31,27)"><b>MEDIA &amp; INVESTOR RELEASE</b></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&#160;</FONT></P>

<p style="text-align: right;"><strong></strong></p>

<P STYLE="text-align: left"><FONT STYLE="font-size: 12pt"><B>Novartis investigational iptacopan Phase III study demonstrates clinically
meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)</B></FONT><P STYLE="text-align: left"><strong>Ad hoc announcement pursuant to Art. 53 LR</strong></p>

<ul type="disc">

<LI STYLE="text-align: left"><em>Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan
vs placebo in proteinuria reduction</em><sup><em>1</em></sup></li></ul>

<ul type="disc">

<LI STYLE="text-align: left"><em>Iptacopan is an investigational, first-in-class, oral factor B inhibitor targeting the alternative pathway of the complement system</em><sup><em>2&#8211;4</em></sup></li></ul>

<ul type="disc">

<LI STYLE="text-align: left"><em>IgAN is a complement-mediated kidney disease, affects mostly young adults, and is a major cause of chronic kidney disease and
kidney failure worldwide</em><sup><em>5&#8211;9</em></sup></li></ul>

<ul type="disc">

<LI STYLE="text-align: left"><em>Novartis plans to review interim results with FDA to enable a potential regulatory submission for accelerated approval; study
continues with final readout (24 months) in 2025</em><sup><em>4</em></sup></li></ul>

<ul type="disc">

<li><em>APPLAUSE-IgAN is the third positive Phase III trial for iptacopan and development program is ongoing across five indications;
regulatory review is underway for paroxysmal nocturnal hemoglobinuria (PNH) in the US and EU</em><sup><em>10,11</em></sup></li></ul>

<p><strong>Basel, October 2, 2023</strong> &#8212; Novartis today announced positive top-line results from the pre-specified interim analysis
of the Phase III APPLAUSE-IgAN study (NCT04578834) at 9 months<sup>1</sup>. Iptacopan, an investigational factor B inhibitor targeting
the alternative complement pathway, demonstrated superiority versus placebo in proteinuria (protein in urine) reduction and provided a
clinically meaningful and highly statistically significant proteinuria reduction on top of supportive care in patients with IgA nephropathy
(IgAN), a complement-mediated disease<sup>1&#8211;4</sup>. In the study, the safety profile of iptacopan (200 mg twice daily) was consistent
with previously reported data<sup>1,3,4</sup>. The study continues in a double-blind fashion to evaluate iptacopan&#8217;s ability to
slow IgAN progression by measuring estimated glomerular filtration rate (eGFR) slope over 24 months &#8211; the primary endpoint at the
study end with topline results expected in 2025<sup>4</sup>.&#160;</p>

<p>&#8220;These positive data from the Phase III APPLAUSE study reinforce the potential of iptacopan to provide clinically meaningful
benefit to patients with IgAN, a debilitating disease that affects mostly young adults,&#8221; said Shreeram Aradhye, M.D., President,
Development and Chief Medical Officer, Novartis. &#8220;We are excited about this milestone in the development of our factor B inhibitor
of the alternative complement pathway and remain focused on further advancing our portfolio of renal programs through pivotal trials.&#8221;&#160;</p>

<p>It is estimated that approximately 25 people per million worldwide are newly diagnosed with IgAN each year<sup>8</sup>. Up to 30% of
people who have IgAN with persistent higher levels of proteinuria (&#8805;1 g/day) may progress to kidney failure within 10 years<sup>12</sup>.
</p>

<p>There is a need for effective, targeted therapies for IgAN that slow or prevent progression to kidney failure<sup>6,13&#8211;15</sup>.&#160;Although
current supportive care and treatment can help, they don&#8217;t address a key pathogenic step in the progression of IgAN: activation
of the complement system<sup>16</sup>. </p>

<p>Discovered and developed by Novartis, iptacopan aims to address IgAN and other complement-mediated diseases by inhibiting factor B,
a protease essential to the alternative complement pathway<sup>2</sup>. </p>

<p>Iptacopan is under review by regulators following positive Phase III results in paroxysmal nocturnal hemoglobinuria (APPLY-PNH [NCT04558918]
and APPOINT-PNH [NCT04558918])<sup>10,11</sup>. Iptacopan is also being investigated in Phase III studies for C3 glomerulopathy (APPEAR-C3G
[NCT04817618]), atypical hemolytic uremic syndrome (APPELHUS [NCT04889430]) and immune complex membranoproliferative glomerulonephritis
(APPARENT [NCT05755386]). With the recent acquisition of Chinook Therapeutics, the Novartis renal portfolio expands with two additional
late-stage medicines in development for IgAN, complementing the existing pipeline<sup>17</sup>.&#160;</p>

<p>Novartis intends to submit for possible accelerated approval with the FDA in 2024.&#160;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P><strong>About the study&#160;</strong><br />APPLAUSE-IgAN (NCT04578834) is a Phase III multicenter, randomized, double-blind, placebo-controlled,
parallel-group study to evaluate the efficacy and safety of twice-daily oral iptacopan (200mg) in 470 adult primary IgAN patients<sup>4,18</sup>.&#160;&#160;</p>

<p>The two primary endpoints of the study for the interim and final analysis, respectively, are proteinuria reduction at 9 months as measured
by urine protein to creatinine ratio (UPCR), and the annualized total estimated glomerular filtration rate (eGFR) slope over 24 months<sup>4,18</sup>.&#160;&#160;<br />At
the time of final analysis, the following secondary endpoints will also be assessed: proportion of participants reaching (UPCR) &lt;1g/g
without receiving corticosteroids/immunosuppressants or other newly approved drugs or initiating new background therapy for treatment
of IgAN or initiating kidney replacement therapy (KRT), time from randomization to first occurrence of composite kidney failure endpoint
event (reaching either sustained &#8805;30% decline in eGFR relative to baseline or sustained eGFR &lt;15 mL/min/1.73m2 or maintenance
dialysis or receipt of kidney transplant or death from kidney failure), change from baseline to 9 months in the fatigue scale measured
by the Functional Assessment Of Chronic Illness Therapy-Fatigue questionnaire<sup>4,18</sup>.&#160;</p>

<p><strong>About IgA nephropathy (IgAN)&#160;</strong><br />IgAN is a progressive, rare, complement-mediated kidney disease that mostly
affects young adults<sup>2&#8211;4,7</sup>. Each year, approximately 25 people per million worldwide are newly diagnosed with IgAN<sup>8</sup>.&#160;&#160;</p>

<p>In IgAN, autoimmune reaction to an abnormal form of IgA results in formation of immune complexes that deposit in the kidney<sup>6,13,19&#8211;22</sup>.
These immune complexes trigger an inflammatory response leading to progressive kidney damage and loss of kidney function<sup>6,13,19&#8211;22</sup>.
Up to 30% of people who have IgAN with persistent higher levels of proteinuria (&#8805;1 g/day) may progress to kidney failure within
10 years<sup>12</sup>.&#160;</p>

<p>There is a need for effective, targeted therapies for IgAN that slow or prevent progression to kidney failure<sup>6,13&#8211;15</sup>.&#160;</p>

<p><strong>About iptacopan&#160;</strong><br />Iptacopan is an oral, proximal complement inhibitor that binds factor B and inhibits the
alternative complement pathway<sup>2&#8211;4</sup>.&#160;</p>

<p>Discovered at the Novartis Biomedical Research, iptacopan is currently in development for a range of complement-mediated diseases including
paroxysmal nocturnal hemoglobinuria (PNH), immunoglobulin A nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex membranoproliferative
glomerulonephritis (IC-MPGN) and atypical hemolytic uremic syndrome (aHUS).&#160;&#160;</p>

<p>Based on disease prevalence, unmet needs and data from Phase II studies, iptacopan has received FDA Breakthrough Therapy Designation
in PNH, FDA Breakthrough Therapy Designation in C3G, orphan drug designations from the FDA and EMA in PNH and C3G, EMA PRIME designation
for C3G, and EMA orphan drug designation in IgAN<sup>23&#8211;26</sup>.&#160;</p>

<p><B>Disclaimer</B><BR />This press release contains forward-looking statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as &#8220;potential,&#8221; &#8220;will,&#8221;
&#8220;may,&#8221; &#8220;expect,&#8221; &#8220;investigational,&#8221; &#8220;pipeline,&#8221; &#8220;accelerated,&#8221; &#8220;ongoing,&#8221;
&#8220;estimated,&#8221; &#8220;aims,&#8221; or similar terms, or by express or implied discussions regarding potential marketing approvals,
new indications or labeling for iptacopan, or regarding potential future revenues from iptacopan. You should not place undue reliance
on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are
subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that iptacopan will be submitted or approved for sale or for any additional indications or labeling in any
market, or at any particular time. Nor can there be any guarantee that iptacopan will be commercially successful in the future. In particular,
our expectations regarding iptacopan could be affected by, among other things, the uncertainties inherent in research and development,
including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation
generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement
pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection;
the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the
effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data
security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in
Novartis AG&#8217;s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in
this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.&#160;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P><STRONG>About Novartis</strong><br />Novartis is reimagining medicine to improve and extend people&#8217;s lives. We deliver high-value
medicines that alleviate society&#8217;s greatest disease burdens through technology leadership in R&amp;D and novel access approaches.
In our quest to find new medicines, we consistently rank among the world&#8217;s top companies investing in research and development.
About 103,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.
Find out more at&#160;https://www.novartis.com</p>

<p>Novartis is on Twitter. Sign up to follow @Novartis at&#160;https://twitter.com/novartisnews<br />For Novartis multimedia content,
please visit <strong>https://</strong><strong>www.novartis.com/news/media-library</strong><br />For questions about the site or required
registration, please contact media.relations@novartis.com</p>

<p><B>References</B><BR />1. Novartis data on file.<BR />2. Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B
inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci. 2019;116(16):7926-7931.
doi:10.1073/pnas.1820892116<BR />3. Barratt J, Rovin B, Zhang H, et al. POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY:
RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS. Kidney Int Rep. 2022;7(2):S236.
doi:10.1016/j.ekir.2022.01.577<BR />4. Rizk DV, Rovin BH, Zhang H, et al. Targeting the Alternative Complement Pathway With
Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study. Kidney Int Rep. 2023;8(5):968-979.
doi:10.1016/j.ekir.2023.01.041<BR />5. Lafayette RA, Kelepouris E. Immunoglobulin A Nephropathy: Advances in Understanding of
Pathogenesis and Treatment. Am J Nephrol. 2018;47(Suppl. 1):43-52. doi:10.1159/000481636<BR />6. Rizk DV, Maillard N, Julian BA, et
al. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy. Front Immunol. 2019;10:504.
doi:10.3389/fimmu.2019.00504<BR />7. Lai KN, Tang SCW, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primer. 2016;2(1):16001.
doi:10.1038/nrdp.2016.1<BR />8. McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a
systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-430. doi:10.1093/ndt/gfq665<BR />9. Penfold RS,
Prendecki M, McAdoo S, Tam FW. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renov Dis.
2018;Volume 11:137-148. doi:10.2147/IJNRD.S129227<BR />10. Novartis Phase III APPOINT-PNH trial shows investigational oral
monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-na&#239;ve PNH
patients. Novartis. Accessed September 27,
2023.&#160;https://www.novartis.com/news/media-releases/novartis-phase-iii-appoint-pnh-trial-shows-investigational-oral-monotherapy-iptacopan-improves-hemoglobin-near-normal-levels-leading-transfusion-independence-all-treatment-naive-pnh-patients<BR />11.
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over
anti-C5. Novartis. Accessed September 27,
2023.&#160;https://www.novartis.com/news/media-releases/novartis-presents-pivotal-phase-iii-apply-pnh-data-ash-demonstrating-investigational-oral-monotherapy-iptacopan-superiority-over-anti-c5<BR />12.
Reich HN, Troyanov SAA, Scholey JW, Cattran DC. Remission of Proteinuria Improves Prognosis in IgA Nephropathy. J Am Soc Nephrol.
2007;18(12):3177-3183. doi:10.1681/ASN.2007050526<BR />13. Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice
Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-S276. doi:10.1016/j.kint.2021.05.021<BR />14.
Ricklin D, Lambris JD. New milestones ahead in complement-targeted therapy. Semin Immunol. 2016;28(3):208-222.
doi:10.1016/j.smim.2016.06.001<BR />15. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and
treatment of IgA nephropathy. Kidney Int. 2012;81(9):833-843. doi:10.1038/ki.2011.501<BR />16. Cheung CK, Rajasekaran A, Barratt J,
Rizk DV. An Update on the Current State of Management and Clinical Trials for IgA Nephropathy. J Clin Med. 2021;10(11):2493.
doi:10.3390/jcm10112493<BR />17. Novartis completes acquisition of Chinook Therapeutics. Novartis. Accessed September 27,
2023.&#160;https://www.novartis.com/news/media-releases/novartis-completes-acquisition-chinook-therapeutics<BR />18. Novartis
Pharmaceuticals. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study to Evaluate the
Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients. clinicaltrials.gov; 2022. Accessed September 21,
2022.&#160;https://clinicaltrials.gov/ct2/show/NCT04578834<BR />19. Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc
Nephrol. 2017;12(4):677-686. doi:10.2215/CJN.07420716<BR />20. Medjeral-Thomas NR, O&#8217;Shaughnessy MM. Complement in IgA
Nephropathy: The Role of Complement in the Pathogenesis, Diagnosis, and Future Management of IgA Nephropathy. Adv Chronic Kidney
Dis. 2020;27(2):111-119. doi:10.1053/j.ackd.2019.12.004<BR />21. Maillard N, Wyatt RJ, Julian BA, et al. Current Understanding of
the Role of Complement in IgA Nephropathy. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000<BR />22. Suzuki H,
Kiryluk K, Novak J, et al. The Pathophysiology of IgA Nephropathy. J Am Soc Nephrol. 2011;22(10):1795-1803.
doi:10.1681/ASN.2011050464<BR />23. Novartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy
Designation for PNH and Rare Pediatric Disease Designation for C3G. Novartis. Accessed September 22,
2022.&#160;https://www.novartis.com/news/media-releases/novartis-investigational-oral-therapy-iptacopan-lnp023-receives-fda-breakthrough-therapy-designation-pnh-and-rare-pediatric-disease-designation-c3g<BR />24.
Novartis data on file.<BR />25. Novartis announces European Medicines Agency (EMA) has granted orphan drug designation for iptacopan
(LNP023) in IgA nephropathy (IgAN). Novartis. Accessed September 22,
2022.&#160;https://www.novartis.com/news/media-releases/novartis-announces-european-medicines-agency-ema-has-granted-orphan-drug-designation-iptacopan-lnp023-iga-nephropathy-igan<BR />26.
Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G). Novartis.
Accessed September 22,
2022.&#160;https://www.novartis.com/news/media-releases/novartis-received-european-medicines-agency-ema-prime-designation-iptacopan-lnp-c3-glomerulopathy-c3g</P>

<P STYLE="font-size: 10pt; margin: 0">&#160;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0"></P>

<P STYLE="margin: 0; font-size: 10pt; font-weight: bold"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"># # #</P>

<P STYLE="margin: 0; font-size: 10pt; text-align: center">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">
        <P STYLE="font-size: 10pt; font-weight: bold; margin: 0">Novartis Media Relations</P>
        <P STYLE="font-size: 10pt; margin: 0">E-mail: media.relations@novartis.com</P>
        <P STYLE="font-size: 10pt; margin: 0">&#160;</P></TD>
    <TD>&#160;</TD>
    <TD COLSPAN="2">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Central</TD>
    <TD COLSPAN="2">&#160;</TD>
    <TD>North America</TD>
    <TD COLSPAN="2">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Richard Jarvis</TD>
    <TD COLSPAN="2">+41 79 584 2326</TD>
    <TD>Julie Masow</TD>
    <TD COLSPAN="2">+1 862 579 8456</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Anja von Treskow</TD>
    <TD COLSPAN="2">+41 79 392 9697</TD>
    <TD>Michael Meo</TD>
    <TD COLSPAN="2">+1 862 274 5414</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Anna Sch&#228;fers</TD>
    <TD COLSPAN="2">+41 79 801 7267</TD>
    <TD>
        <P STYLE="font-size: 10pt; margin: 0"></P>
        <P STYLE="font-size: 10pt; margin: 0">Marlena Abdinoor</P></TD>
    <TD COLSPAN="2">
        <P STYLE="font-size: 10pt; margin: 0"></P>
        <P STYLE="font-size: 10pt; margin: 0; color: #221F1F"><FONT STYLE="background-color: white">+1 617 335 9525</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font-size: 10pt; margin: 0">Switzerland</P>
        <P STYLE="font-size: 10pt; margin: 0"></P></TD>
    <TD COLSPAN="2">
        <P STYLE="font-size: 10pt; margin: 0">&#160;</P>
        <P STYLE="font-size: 10pt; margin: 0"></P>
        <P STYLE="font-size: 10pt; margin: 0"></P></TD>
    <TD>&#160;</TD>
    <TD COLSPAN="2">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Satoshi Sugimoto</TD>
    <TD COLSPAN="2">+41 79 619 2035</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD COLSPAN="2">&#160;</TD>
    <TD>&#160;</TD>
    <TD COLSPAN="2">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">
        <P STYLE="font-size: 10pt; font-weight: bold; margin: 0">Novartis Investor Relations</P>
        <P STYLE="font-size: 10pt; margin: 0">Central investor relations line:</P>
        <P STYLE="font-size: 10pt; margin: 0">+41 61 324 7944</P>
        <P STYLE="font-size: 10pt; margin: 0">E-mail: investor.relations@novartis.com</P>
        <P STYLE="font-size: 10pt; margin: 0">&#160;</P></TD>
    <TD COLSPAN="3">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Central</TD>
    <TD>&#160;</TD>
    <TD COLSPAN="2">North America</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Samir Shah</TD>
    <TD>+41 61 324 7944</TD>
    <TD COLSPAN="2">Sloan Simpson</TD>
    <TD>+1 862 345 4440</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Nicole Zinsli-Somm</TD>
    <TD>+41 61 324 3809</TD>
    <TD COLSPAN="2">Parag Mahanti</TD>
    <TD>+1 973 876 4912</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Isabella Zinck</TD>
    <TD>+41 61 324 7188</TD>
    <TD COLSPAN="2">&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR>
    <TD STYLE="width: 26%">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 23%">&#160;</TD>
    <TD STYLE="width: 28%">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 21%">&#160;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; margin: 0"></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&#160;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; font-size: 10pt">
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Novartis AG</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 2, 2023</font></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ PAUL PENEPENT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Penepent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head Group Financial Reporting and Accounting</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#F17AI9@  34T *@    @ !0$.  (
M   6   (5@$Q  (    F   (;(=I  0    !   (DIR;  $    L   0LNH<
M  <   @,    2@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     &YO=F%R=&ES7VQO9V]?<F=B7W!O<P!!9&]B92!);&QU<W1R871O<B!#
M0R R,#$U("A-86-I;G1O<V@I   !ZAP !P  " P   BD     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      !N &\ =@!A '( = !I ',
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MS_\ $ITHL.C$+)<./?'EK^+5^79S.69Y_0R^'PTVI2_/\K6\V?T9PI2I\/\
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M!GPBWB2[^'/B+Q=X9M[9I]2U31'M3'8 ''[U9)D?&#G<JD>I%>VU\[_M:?\
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M#?0?@UXZU+QQIC3K?Z2@T]9(# X24%FN@GRL0.&/7C->C:=^T2__  OSP/\
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M<T:RQMU5UR#^!HHJ2AP 50J@*HZ 4M%% !1110 4444 %%%% !1110 4444
M%%%% !6;J&CZ1J\(CU;2K/5(QT6[MDE _!@:**:;3NA-)JS':?I6EZ19FWTG
:3;72[<G)BM+=8E_)0!6A110VV[L$DE9'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
